Qiagen and Gencurix have entered a partnership to develop cancer tests for clinical diagnostics. The companies said Wednesday the partnership combines Qiagen's QIAcuityDx platform, a digital ...

As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com. About Tracer Biotechnologies ...

On Friday, Qiagen (NYSE:QGEN) announced a new commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain ...

QIAGEN N.V. QGEN recently signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic ...

Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%.

Qiagen N.V. ended FY2024 with just over $1.15 billion in cash and marketable securities on its balance sheet against just under $1.35 billion in long-term debt.

This is the first QIAstat-Dx panel to receive FDA clearance in 2025 and comes after four FDA clearances were granted in 2024 for QIAstat-Dx panels. These panels in 2024 are designed to address ...

Qiagen and AstraZeneca are expanding their diagnostics partnership, with plans to explore the use of genomic profiling in chronic diseases beyond cancer. The long-time collaborators, which ...

Qiagen typically operates with an easy-to-manage balance sheet. As of March 2024, the company owed $1.5 billion of debt and held $0.9 billion of cash and investments on its balance sheet ...

QIAGEN N.V. QGEN recently announced the completion of the acquisition of Verogen — a provider of next-generation sequencing (NGS) technologies to increase its position in human identification ...